Veradermics, INC 8-K filings

Veradermics announces positive Phase 2 results for VDPHL01 in female hair loss, completes enrollment for a key Phase 2/3 trial, and reports a strong cash position extending operational runway to 2030.

Veradermics, Inc. announced positive topline results from its Phase 2 clinical trial (Study 207) for VDPHL01, an oral extended-release minoxidil formulation, in females with mild-to-moderate pattern hair loss.

Veradermics announced positive Phase 2/3 results for its pattern hair loss treatment VDPHL01, bolstered by a strong cash position from recent financing.

Veradermics, Incorporated has closed a $30 million private placement of pre-funded warrants to institutional investors.

Veradermics, Incorporated announced a preliminary unaudited cash and marketable securities balance of $390.8 million as of March 31, 2026.

Veradermics, Inc. announced positive topline results from its Phase 2/3 clinical trial (Study 302) evaluating VDPHL01 for mild-to-moderate pattern hair loss in males, meeting all primary and key secondary endpoints.

Veradermics reported higher 2025 operating losses, closed a $294.8M upsized IPO in Feb. 2026, completed enrollment in two male Phase 3 trials of VDPHL01, and guided to topline data in 1H and 2H 2026.